Meticulous Research®, a leading global market research company, published a research report titled, 'North America Pharmaceutical Contract Development and Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma] - Forecast to 2030.’
Download Sample Report Here : https://www.meticulousresearch.com/download-sample-report/cp_id=5749
According to this latest publication from Meticulous Research®, the North America pharmaceutical contract development and manufacturing market is expected to reach $105.42 billion by 2030 at a CAGR of 7.1% from 2023 to 2030.The growth of the North America pharmaceutical contract development and manufacturing market is attributed to the rising incidence & prevalence of chronic illness, rising awareness of overall health and treatment availability, growing geriatric population in the region, rising pharmaceutical R&D expenditure, low-cost manufacturing advantages, increasing government funding for drug development and research, improving healthcare infrastructure, and growing healthcare spending. The lack of skilled professionals is challenging the growth of this market. High demand for personalized medicine, cell therapies, and gene therapies, and growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) market are providing opportunities for market growth.
Key Players
The key players operating in the North America pharmaceutical contract development and manufacturing market are Thermo Fisher Scientific Inc. (U.S.), Catalent, Inc. (U.S.), C.H. Boehringer Sohn AG & CO. KG. (Germany), Synoes Health, Inc. (U.S.), Curia Global, Inc. (U.S.), Cambrex Corporation (U.S.), FUJIFILM Diosynth Biotechnology (U.S.), Samsung Biologics (South Korea), Siegfried Holding AG (Switzerland), Aenova Group (Germany), WuXi Biologics (China), and Vetter Pharma International GmbH (Germany).
North America Pharmaceutical Contract Development and Manufacturing Market: Future Outlook
The North America pharmaceutical contract development and manufacturing market is segmented by Type (Pharmaceutical Manufacturing Services {Active Pharmaceutical ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services [Parenteral/Injectable Manufacturing Services, Tablet Manufacturing Services, Capsule Manufacturing Services, Oral Liquid Manufacturing Services, and Other Formulations]}, Drug Development Services, and Biologics Manufacturing Services {Active Pharmaceutical ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services}), End User (Large Pharmaceutical Companies, Small & Mid-Size Pharmaceutical Companies, and Generic Pharmaceutical Companies), and Countries. The study also evaluates industry competitors and analyzes their market share at the country level.
Speak to Analyst : https://www.meticulousresearch.com/speak-to-analyst/cp_id=5749
Among all types studied in this report, in 2023, the pharmaceutical manufacturing services segment is expected to account for the largest share of the North America pharmaceutical contract development and manufacturing market. The pharmaceutical manufacturing services segment is further segmented into active pharmaceutical ingredient (API) manufacturing services and finished dosage forms (FDF) manufacturing services. The largest share of this segment is attributed to the need to reduce manufacturing costs, to bring a new drug to the market quickly at the lowest possible cost, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs.
Among all end users studied in this report, the generic pharmaceutical companies segment is expected to register the highest CAGR over the forecast period. Factors such as increasing competition in the generic market leading to pricing pressure and the growing inclination of these companies towards the use of cutting-edge technologies offered by contract development and manufacturing companies are also contributing to the highest CAGR of the segment.
Geographic Review
This research report comprehensively analyzes major countries U.S. and Canada. In 2023, the U.S. is expected to account for the largest share of the North America pharmaceutical contract development and manufacturing market. The largest share of the U.S. is attributed to the presence of major pharmaceutical companies, drug shortages, and the high spending power of small and mid-sized pharmaceutical organizations. In addition, smaller companies are making moves in cell and gene therapy manufacturing in the U.S. For instance, in May 2021, Catalent Inc. (U.S.) acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its 32,400 square-foot (3,010 square-meter) facility in Gosselies, Belgium. The facility will accommodate Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and provide the opportunity for the immediate growth of Catalent’s pDNA service offering, which was recently acquired from Delphi Genetics to support the growing cell and gene therapy pipeline.
Quick Buy : https://www.meticulousresearch.com/Checkout/74525052
Key questions answered in the report:
• Which are the high-growth market segments in terms of type, end user, and country?
• What was the historical market for pharmaceutical contract development and manufacturing services in North America?
• What are the market forecasts and estimates for the period 2023–2030?
• What are the major drivers, restraints, challenges, and opportunities in the North America pharmaceutical contract development and manufacturing market?
• Who are the major players in the North America pharmaceutical contract development and manufacturing market?
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research